Table 1 Key trials in ovarian cancer immunotherapy

Vald, Edwards Cancer Immunol Immunother 2010

Recurrent, platinum resistant ovarian cancer

Interleukin-2 i.p.

CR: 4

Median Survival:

6 × 10⁵ IU/ml weekly × 16

PR: 2

Non-Responder:

SD: 7

1.5 years

Responders: not reached

(24 -120+ months)

Hodi, Dranoff

Recurrent metastatic ovarian cancer

CTLA-4 Blockade:

CR: 0

Duration of Response:

PNAS 2008

Ipilupimab i.v. 3 mg/kg q 2 – 3 months

PR: 1

SD: 2,4,6+ Months

SD: 3

PR: 35+ Months

Diefenbach, Dupont

“High Risk” ovarian cancer after surgery and 1^st line chemo

NY-ESO-1b peptide (position 157–165; 100 μg) + 0.5 mL Montanide ISA-51 s.c. q 3 weeks × 5

NA

Median PFS: 13 months

Clin Cancer Res 2008

6/9 patients recurred

3 patient disease free after 25, 38, and 52

Fujita,Tanaka Clin Cancer Research 1995

NED after surgery and 1^st line chemo

1.0 – 4.4 × 10⁹ TIL after 1^st line chemo

NA

3-year DFS:

TIL: 82.1%

Control: 54.5%

3-year DFS, residual disease after surgery

TIL: 76.2%

Control: 33.3%

Chu, June

Consolidation after 1^st line treatment or secondary debulking

Her-2/neu, hTERT, PADRE-loaded Dendritic cells +/− Cyclophosphamide

NA

5 recurrences

Cancer Immunol Immunother 2012

6 patients NED at 36 months

3-year OS 90%

Odunsi, Jaeger

Consolidation after 1^st line treatment

I.d. rV-NY-ESO-1,

NA

PFS: 21 months

PNAS 2012

3.1 × 10⁷ PFU, monthly s.c.

OS: 48 months

rF-NY-ESO-1, 7.41 × 10⁷ PFU for 6 mo.

Rahma, Khleif

HLA-A2.1 + stage III, IV, or recurrent ovarian

Arm A: s.c. wt p53:264–272 peptide with Montanide and GM-CSF.

NA

Arm A:

Cancer Immunol Immunother 2012

Immune responses 9/13 patients (69%), PFS: 4.2 months

Cancer over-expressing the p53 protein, no evidence of disease

Arm B: i.v. wt p53:264–272 peptide-pulsed dendritic cells IV

OS: 40.8 months

IL-2 in both cohorts

Arm B:

Immune responses 5/6 patients (83%)

PFS: 8.7 months

OS: 29.6 months